novel
coronaviru
cov
emerg
saudi
arabia
june
caus
agent
sever
respiratori
diseas
call
middl
east
respiratori
syndrom
mer
thu
far
almost
diagnos
case
despit
increas
surveil
identif
mani
new
case
case
fatal
rate
remain
high
current
approxim
although
high
number
case
littl
known
mechan
pathogenesi
diseas
progress
human
poorli
describ
clinic
featur
rang
asymptomat
infect
acut
respiratori
distress
syndrom
multiorgan
failur
major
patient
succumb
merscov
comorbid
diseas
thought
sever
immunocompromis
patient
howev
actual
mechan
diseas
remain
elucid
viru
shown
replic
human
primari
epitheli
ex
vivo
human
lung
cultur
especi
noncili
bronchial
epitheli
cell
alveolar
type
ii
pneumocyt
receptor
identifi
dipeptidyl
peptidas
express
cell
type
merscov
shed
higher
patient
sever
diseas
manifest
compar
milder
case
laboratori
recent
develop
two
nonhuman
primat
model
mer
util
rhesu
macaqu
common
marmoset
rhesu
macaqu
develop
mild
pneumonia
upon
intratrach
inocul
merscov
model
viru
replic
within
respiratori
tract
modest
level
detect
oral
nasal
swab
howev
clinic
diseas
promin
within
first
day
inocul
anim
show
sign
diseas
resolut
soon
diseas
rhesu
like
model
mild
form
human
diseas
infect
selflimit
clinic
sign
symptom
mild
effort
examin
whether
immun
statu
individu
influenc
diseas
sever
pathogen
replic
kinet
viru
downregul
immun
system
rhesu
macaqu
use
immunosuppress
drug
found
merscov
replic
significantli
higher
titer
dissemin
outsid
respiratori
tract
immunosuppress
anim
yet
patholog
markedli
reduc
anim
show
diseas
immunopathogen
compon
use
studi
anim
approv
institut
anim
care
use
committe
rocki
mountain
laboratori
experi
perform
follow
guidelin
associ
assess
accredit
laboratori
anim
care
certifi
staff
approv
facil
guidelin
basic
principl
unit
state
public
health
servic
polici
human
care
use
laboratori
anim
guid
care
use
laboratori
anim
follow
procedur
carri
anesthesia
use
ketamin
train
personnel
veterinarian
supervis
effort
made
provid
welfar
anim
minim
suffer
anim
human
euthan
endpoint
studi
day
postinocul
exsanguin
deep
anesthesia
standard
oper
procedur
merscov
approv
institut
biosafeti
committe
rock
mountain
laboratori
sampl
inactiv
carri
accord
approv
standard
oper
procedur
prior
remov
high
contain
middl
east
respiratori
syndrom
coronaviru
isol
propag
vero
cell
dmem
sigma
supplement
fb
logan
mm
lglutamin
lonza
uml
penicillin
streptomycin
gibco
five
rhesu
macaqu
femal
weigh
kg
year
age
enrol
studi
immunosuppress
anim
achiev
administr
cyclophosphamid
cyp
roxan
laboratori
mgkg
dissolv
ml
meal
supplement
boost
deliv
via
orogastr
tube
anesthesia
everi
day
start
day
prior
viru
inocul
end
day
inocul
dexamethason
dex
mgkg
daili
subcutan
inject
begin
day
prior
viru
inocul
end
day
inocul
mock
immunosuppress
perform
follow
schedul
orogastr
feed
contain
cyp
inject
consist
steril
pb
immunosuppress
confirm
monitor
white
blood
cell
wbc
popul
use
hemavet
drew
scientif
inocul
merscov
dilut
ml
dmem
deliv
via
intratrach
ml
oral
ml
nasal
ml
ocular
ml
rout
previous
describ
clinic
exam
perform
day
rel
viru
inocul
blood
obtain
time
well
nasal
oral
swab
chest
radiograph
start
day
six
day
inocul
five
anim
euthan
necropsi
perform
obtain
sampl
follow
tissu
lung
six
lobe
bronchi
oronasopharynx
trachea
tonsil
heart
liver
spleen
kidney
adren
gland
pancrea
inguin
axillari
mesenter
mediastin
lymph
node
use
onestep
realtim
quantit
rtpcr
measur
viral
rna
sampl
rna
extract
swab
use
qiaamp
viral
rna
extract
kit
tissu
use
rneasi
kit
qiagen
rna
use
along
merscovspecif
primerprob
set
use
rotorgen
probe
kit
qiagen
tissu
cultur
infecti
dose
equival
calcul
compar
cycl
threshold
valu
standard
curv
gener
viru
stock
known
titer
primer
probe
sequenc
describ
previous
tissu
fix
neutral
buffer
formalin
two
chang
minimum
day
process
sakura
tissu
tek
h
autom
schedul
use
grade
seri
ethanol
xylen
paraplast
extra
embed
tissu
section
dri
overnight
prior
stain
immunohistochemistri
ihc
tissu
process
use
discoveri
xt
autom
processor
dapmap
kit
ventana
specif
primari
antibodi
use
antihcovemc
polyclon
rabbit
antibodi
cov
dilut
rabbit
monoclon
primari
antibodi
appli
neat
thermo
scientif
dilut
ihc
stain
section
scan
aperio
scanscop
xt
aperio
technolog
inc
vista
ca
usa
analyz
use
imagescop
posit
pixel
count
algorithm
version
approxim
mm
squar
evalu
magnif
default
paramet
posit
pixel
count
hue
width
use
assess
contribut
immun
respons
protect
mer
diseas
immunosuppress
three
rhesu
macaqu
use
cyp
dex
day
prior
inocul
merscov
two
anim
use
mock
immunosuppress
control
receiv
ident
inoculum
throughout
immunosuppress
monitor
wbc
popul
blood
determin
efficaci
immunosuppress
regimen
total
wbc
count
decreas
approxim
twofold
compar
control
anim
respons
cyp
dex
administr
time
merscov
inocul
reduct
due
decreas
measur
cell
type
lymphocyt
neutrophil
monocyt
eosinophil
basophil
figur
follow
merscov
inocul
absolut
count
cell
popul
remain
low
immunosuppress
anim
suggest
inabl
respond
infect
convers
two
mock
immunosuppress
anim
increas
number
monocyt
eosinophil
respons
infect
quantifi
immunosuppress
tissu
level
spleen
mediastin
lymph
node
anim
stain
immunohistochem
cell
b
cell
marker
respect
postmortem
amount
stain
quantit
assess
use
imag
softwar
quantiti
stain
approxim
lower
spleen
mediastin
lymph
node
immunosuppress
anim
likewis
lower
spleen
lower
lymph
node
show
gener
reduct
lymphocyt
tissu
confirm
suppress
drug
therapi
effect
reduc
immun
cell
popul
figur
b
immunosuppress
also
disrupt
normal
architectur
tissu
oral
nasal
swab
sampl
obtain
daili
throughout
cours
merscov
infect
monitor
shed
viral
rna
shed
detect
anim
detect
viral
rna
occur
earlier
persist
longer
sever
log
higher
immunosuppress
anim
compar
control
anim
figur
b
viral
rna
detect
day
postinocul
nasal
swab
three
immunosuppress
anim
oral
swab
two
anim
wherea
control
anim
neg
time
point
assess
viru
replic
tissu
enlist
three
rhesu
macaqu
previou
studi
serv
histor
control
along
two
control
studi
anim
given
inoculum
stock
viru
via
rout
euthan
day
postinocul
compar
viral
abund
lung
six
lobe
control
studi
histor
control
signific
differ
geometr
mean
viral
rna
abund
two
group
although
histor
control
slightli
measur
viral
rna
figur
howev
immunosuppress
anim
significantli
increas
merscov
replic
measur
rna
abund
lung
test
p
similarli
significantli
viru
detect
sever
respiratori
respiratori
tractassoci
tissu
includ
bronchi
trachea
tonsil
mediastin
lymph
node
immunosuppress
anim
compar
control
figur
test
p
assess
viral
dissemin
tissu
outsid
respiratori
tract
immunosuppress
anim
posit
low
level
viral
rna
sever
tissu
includ
liver
spleen
well
sever
lymph
node
wherea
viru
undetect
outsid
respiratori
tract
control
anim
except
one
inguin
lymph
node
sampl
tabl
sampl
anim
evalu
presenc
histopatholog
chang
anim
except
develop
degre
pulmonari
patholog
upon
examin
tissu
follow
necropsi
day
inocul
figur
lesion
character
multifoc
mildtomark
interstiti
pneumonia
frequent
center
termin
bronchiol
pneumonia
character
thicken
alveolar
septa
congest
edema
fibrin
small
moder
number
macrophag
neutrophil
alveoli
contain
moder
number
pulmonari
macrophag
neutrophil
lung
mark
chang
abund
alveolar
edema
fibrin
format
hyalin
membran
multifoc
type
ii
pneumocyt
hyperplasia
note
also
perivascular
infiltr
inflammatori
cell
within
adjac
affect
area
lung
sampl
lung
lobe
anim
individu
score
presenc
extent
patholog
chang
score
rang
patholog
multipl
coalesc
inflammatori
foci
fibrin
edema
anim
averag
histolog
score
individu
lung
lobe
score
rang
respect
tabl
immunosuppress
anim
display
much
milder
patholog
averag
score
respect
lobe
show
score
greater
anim
undergo
immunosuppress
develop
sever
pulmonari
patholog
demonstr
littl
viral
antigen
lung
tissu
examin
ihc
figur
reflect
qrtpcr
result
much
less
viral
rna
detect
viral
rna
undetect
mani
individu
lung
lobe
convers
macaqu
undergon
immunosuppress
mild
lung
lesion
demonstr
merscov
viral
antigen
multifoc
throughout
lung
predominantli
within
type
pneumocyt
suggest
pulmonari
patholog
associ
merscov
anim
may
tightli
associ
immun
respons
littl
known
regard
sever
emerg
zoonot
virus
infect
respiratori
tract
caus
diseas
risk
factor
contribut
poor
outcom
virus
thought
caus
diseas
dysregul
immun
respons
wherebi
destruct
infect
cell
secret
proinflammatori
mediat
lead
immunopatholog
case
hantavirus
convers
pathogenesi
caus
virus
correl
defici
ineffici
immun
respons
case
pathogen
virus
affect
young
elderli
immun
compromis
individu
case
influenza
viru
mechan
recent
emerg
merscov
caus
diseas
human
host
factor
associ
either
resist
poor
outcom
known
question
import
develop
countermeasur
either
directli
target
viru
inhibit
replic
modul
immun
respons
limit
immunopathogenesi
earli
epidemiolog
studi
mer
suggest
patient
comorbid
fare
wors
healthi
patient
upon
infect
number
comorbid
correl
wors
outcom
addit
patient
lethal
infect
report
immunosuppress
report
case
diagnos
primarili
patient
alreadi
hospit
includ
rel
larg
number
nosocomi
infect
affect
patient
hospit
outbreak
alhasa
sinc
initi
case
report
addit
case
merscov
infect
confirm
although
mani
new
case
report
health
care
relat
either
stem
patient
health
care
worker
unclear
mani
case
involv
immunocompromis
individu
risk
factor
associ
diseas
infect
includ
weaken
immun
system
chronic
diseas
diabet
cancer
chronic
lung
diseas
well
coinfect
although
comorbid
clearli
affect
statu
immun
respons
acut
immunosuppress
use
drug
done
provid
control
deficit
immun
respons
wherea
immun
dysregul
brought
chronic
diseas
infect
age
complex
phenomenon
involv
defici
immun
respons
chronic
inflammatori
respons
known
yet
describ
complex
chang
instanc
major
patient
diabet
comorbid
sever
other
immunosuppress
hivaid
condit
alter
immun
respons
way
inhibit
normal
cell
function
well
induc
inflammatori
respons
alter
respons
secret
inflammatori
cytokin
immunosuppress
studi
mimic
aspect
human
condit
patient
inhibit
cell
respons
hivinfect
patient
howev
chemic
immunosuppress
use
herein
unlik
mimic
chronic
inflammatori
state
mani
patient
higher
basal
level
immun
activ
associ
condit
may
import
contribut
manifest
clinic
overt
seriou
diseas
follow
merscov
infect
would
impli
immun
system
play
role
pathogenesi
merscov
agre
observ
upon
simpl
immunosuppress
merscov
replic
higher
level
show
greater
dissemin
shed
patholog
actual
reduc
anim
patholog
like
lessen
due
absenc
inflammatori
cell
mediat
observ
histolog
lung
tissu
suggest
viru
might
caus
littl
damag
cell
infect
would
lead
toward
mechan
absenc
effici
immun
respons
allow
viru
replic
high
level
wherea
patholog
attribut
overact
inflammatori
respons
patient
comorbid
prone
possess
support
data
resu
marmoset
anim
model
show
increas
viral
replic
local
immun
respons
play
import
role
pulmonari
sever
diseas
although
perform
studi
control
group
treat
immunosuppress
drug
challeng
would
necessari
comprehens
pictur
immun
statu
anim
time
necropsi
recent
experi
use
humanderiv
blood
cell
shown
infect
merscov
result
dramat
increas
product
cytokin
immun
cellrecruit
chemokin
author
hypothes
inflammatori
respons
could
lead
sever
inflamm
tissu
damag
support
observ
bronchoalveolar
lavag
fluid
human
infect
merscov
contain
high
number
neutrophil
macrophag
furthermor
lymphopenia
associ
diseas
potenti
caus
infiltr
lymphocyt
lung
tissu
egress
blood
take
find
account
envis
model
infect
lung
tissu
resid
immun
cell
alveolar
macrophag
lead
hyperproduct
inflammatori
cytokin
immun
cell
recruit
chemokin
togeth
limit
viru
replic
result
immunopatholog
state
upon
immunosuppress
macaqu
viru
still
abl
infect
replic
lung
tissu
like
induc
local
cytokin
chemokin
express
howev
deplet
immun
cell
popul
upon
chemic
immunosuppress
inhibit
recruit
inflammatori
cell
lung
infect
tissu
thu
limit
patholog
first
direct
experiment
evid
show
merscov
immunopathogen
compon
line
observ
one
patient
south
korea
take
prolong
highdos
corticosteroid
therapi
control
lymphoma
activ
hemolyt
anemia
display
persist
viral
shed
without
clinic
progress
diseas
shed
merscov
extens
immunosuppress
anim
durat
peak
shed
suggest
immun
statu
direct
influenc
viru
shed
subsequ
potenti
transmiss
epidemiolog
analys
merscov
outbreak
south
korea
clearli
show
level
merscov
shed
directli
associ
transmiss
potenti
spreader
statist
lower
ct
valu
compar
nonspread
persist
merscov
shed
immunocompromis
patient
could
therefor
contribut
enhanc
nosocomi
transmiss
yet
specif
treatment
option
identifi
merscov
infect
result
present
herein
show
inflammatori
respons
contribut
pathogen
process
would
suggest
treatment
patient
symptomat
infect
would
benefit
addit
therapi
lessen
inflammatori
respons
especi
lung
base
sole
therapi
aim
control
viru
replic
use
studi
anim
approv
institut
anim
care
use
committe
rocki
mountain
laboratori
experi
perform
follow
guidelin
associ
assess
accredit
laboratori
anim
care
certifi
staff
approv
facil
guidelin
basic
principl
unit
state
public
health
servic
polici
human
care
use
laboratori
anim
guid
care
use
laboratori
anim
follow
procedur
carri
anesthesia
use
ketamin
train
personnel
veterinarian
supervis
effort
made
provid
welfar
anim
minim
suffer
anim
human
euthan
endpoint
studi
day
postinocul
exsanguin
deep
anesthesia
standard
oper
procedur
merscov
approv
institut
biosafeti
committe
rock
mountain
laboratori
sampl
inactiv
carri
accord
approv
standard
oper
procedur
prior
remov
high
contain
jp
df
ew
hf
vm
design
studi
jp
ds
hf
vm
analyz
data
jp
hf
vm
wrote
manuscript
jp
kh
ff
eh
vm
ds
perform
experi
assay
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
